MAP1LC3A and hepatocellular carcinoma: Furthermore, patients with a combination of high Axl and low LC3 expression had the highest risk of HCC recurrence (HR: 6.53, 95% CI: 4.11‐10.4, P < 0.001) and mortality (HR: 6.66, 95% CI: 4.07‐10.9, P < 0.001).